Device Firms Seek Definition Of "New Science," As FDA Mulls Policy Changes
This article was originally published in The Gray Sheet
Executive Summary
FDA must better define what it considers "new science" when deciding how to incorporate emerging data into product reviews and post-market surveillance, and must vet the data carefully before reacting, device companies say